December 3, 2018 @ 7:19 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
Reports of results from the December 1-4 meeting of the American Society of Hematology continue to move biotech stocks. Today it was Incyte’s (INCY) turn. The company announced positive results for a Phase 2 trial evaluating Incyte’s Jakafi in combination...
October 19, 2018 @ 7:52 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
Shares of Incyte  (INCY) climbed 2.51% today on the announcement of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer. The company presented the data at...
August 24, 2018 @ 3:56 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
I am on vacation until August 26. I am using that downtime to catch up on some of the earnings reports I missed during the very busy second quarter earnings season. On July 30 Incyte (INCY) reported second quarter earnings of 26 cents a share, 4 cents below the Wall...
March 15, 2018 @ 6:52 pm | Breaking News, INCY, Jubak Picks Portfolio |
The Food and Drug Administration today announced that its Arthritis Advisory Committee will meet on April 23 to discuss the application by Incyte (INCY) and Eli Lilly (LLY) for approval of baricitinib for the treatment of adult patients with moderately to severely...
March 7, 2018 @ 7:03 pm | Breaking News, INCY, Jubak Picks Portfolio |
When I sold Acadia Pharmaceuticals (ACAD) out of my Jubak Picks portfolio on March 5, one reason I gave was that the catalysts for this biotech were too far out–results from critical drug trials weren’t likely to be reported for two years. The reason to...
December 6, 2017 @ 7:55 pm | Breaking News, INCY, Jubak Picks Portfolio |
On December 4 MacroGenics (MGNX) announced that it had closed on its previously announced (October 25) license agreement with Incyte (INCY). For an upfront payment of $150 million and up to $420 million in milestone payments Incyte gained the exclusive global rights...
October 2, 2017 @ 7:56 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
This qualifies as a horrendous six months for any stock: Shares of Incyte (INCY) are down from $152.66 on March 15 to $115.19 at the close today, October 2. The shares have been even lower, which is one thing giving me some hope that the pain is coming to an end. The...
May 18, 2017 @ 5:35 pm | Breaking News, INCY, Jubak Picks Portfolio, Update |
Shares of Incyte (INCY) are up 7.1% as of 12:30 p.m. New York time on data released before the June meeting of the American Society of Clinical Oncology showing that Incyte’s epacadostat, which is an IDO inhibitor, has proved effective when used in combination...
April 25, 2017 @ 12:02 am | BMY, Breaking News, Jubak Picks Portfolio, Sell |
I’m selling Bristol-Myers Squibb (BMY) out of my Jubak Picks portfolio ahead of Thursday’s report of first quarter earnings. I’m afraid that earnings will confirm what monthly sales reports from Bristol-Myers and competitors have outlined: That the...
November 17, 2016 @ 7:33 pm | INCY, Jubak Picks Portfolio, Update |
Incyte (INCY) has been one of the big movers in the biotech rally after Donald Trump’s victory in the November 8 presidential election. The stock is up 26.7% from the close on November 3 to the close today, November 17. (Incyte is a member of my Jubak Picks...